## Gene Summary
CYP4A11, officially known as cytochrome P450 family 4 subfamily A member 11, is an enzyme encoded by the CYP4A11 gene in humans. It belongs to the cytochrome P450 superfamily, which comprises enzymes involved in the metabolism of a vast array of endogenous and exogenous substances. CYP4A11 is primarily expressed in the liver and kidneys and is involved in the oxidation of fatty acids, particularly in the hydroxylation of lauric acid to 12-hydroxylauric acid. This activity is vital for the maintenance of physiological lipid homeostasis and the production of signaling molecules.

## Gene Drugs, Diseases, Phenotypes, and Pathways
CYP4A11 influences various physiological functions and disease states predominantly through its role in lipid metabolism and blood pressure regulation. Dysregulation in the expression or activity of CYP4A11 has been associated with the development of hypertension, atherosclerosis, and potentially other cardiovascular disorders. The conversion activity of this enzyme towards fatty acids also implicates it in pathways relevant to metabolic syndrome and kidney diseases. Moreover, specific genetic variants of CYP4A11 are linked with altered enzyme activity which can influence blood pressure levels and susceptibility to cardiovascular diseases.

## Pharmacogenetics
In pharmacogenetics, CYP4A11 has been studied, although not as extensively as some other cytochrome P450 enzymes, primarily for its contributions to hypertension pharmacotherapy. Notably, the gene's variants can affect individual responses to antihypertensive drugs, though specific drug associations have not been as clearly defined as seen in other cytochrome P450 related genes. Understanding the variations within CYP4A11 can aid in tailoring personalized treatment approaches for hypertension and potentially for conditions influenced by fatty acid metabolism. However, further research needs to define explicit links between CYP4A11 pharmacogenetics and clinical outcomes to these treatments.